- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00103207
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase II trial is studying how well cetuximab works in treating patients with recurrent or stage IIIB or stage IV lung cancer.
Study Overview
Detailed Description
OBJECTIVES:
Primary
- Determine the objective response rate in patients with recurrent or stage IIIB or IV bronchoalveolar carcinoma (BAC) or adenocarcinoma of the lung with BAC features treated with cetuximab.
Secondary
- Determine the overall survival and time to progression in patients treated with this drug.
- Determine the toxic effects of this drug in these patients.
- Correlate expression of total and phosphorylated epidermal growth factor receptor (EGFR), total and phosphorylated AKT3, and total and phosphorylated MAPKinase with response in patients treated with this drug.
- Determine whether the presence of polymorphisms or mutations in the EGFR gene influences response in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive cetuximab IV over 1-2 hours once on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.
ACTUAL ACCRUAL: A total of 72 patients were accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Aurora Presbyterian Hospital
-
Colorado Springs, Colorado, United States, 80933
- Penrose Cancer Center at Penrose Hospital
-
Denver, Colorado, United States, 80210
- Porter Adventist Hospital
-
Denver, Colorado, United States, 80220
- Rose Medical Center
-
Denver, Colorado, United States, 80218
- Presbyterian - St. Luke's Medical Center
-
Denver, Colorado, United States, 80204
- St. Anthony Central Hospital
-
Denver, Colorado, United States, 80218
- St. Joseph Hospital
-
Denver, Colorado, United States, 80224-2522
- CCOP - Colorado Cancer Research Program
-
Englewood, Colorado, United States, 80110
- Swedish Medical Center
-
Grand Junction, Colorado, United States, 81502
- St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
-
Greeley, Colorado, United States, 80631
- North Colorado Medical Center
-
Lone Tree, Colorado, United States, 80124
- Sky Ridge Medical Center
-
Longmont, Colorado, United States, 80502
- Hope Cancer Care Center at Longmont United Hospital
-
Loveland, Colorado, United States, 80539
- McKee Medical Center
-
Pueblo, Colorado, United States, 81004
- St. Mary - Corwin Regional Medical Center
-
Thornton, Colorado, United States, 80229
- North Suburban Medical Center
-
Wheat Ridge, Colorado, United States, 80033
- Exempla Lutheran Medical Center
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus
-
Jacksonville, Florida, United States, 32207
- Baptist Cancer Institute - Jacksonville
-
-
Illinois
-
Aurora, Illinois, United States, 60504
- Rush-Copley Cancer Care Center
-
Decatur, Illinois, United States, 62526
- Decatur Memorial Hospital Cancer Care Institute
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates, Limited - West
-
Rockford, Illinois, United States, 61104-2315
- Swedish-American Regional Cancer Center
-
Springfield, Illinois, United States, 62781-0001
- Regional Cancer Center at Memorial Medical Center
-
Urbana, Illinois, United States, 61801
- Carle Cancer Center at Carle Foundation Hospital
-
Urbana, Illinois, United States, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Michigan City, Indiana, United States, 46360
- Saint Anthony Memorial Health Centers
-
-
Iowa
-
Ames, Iowa, United States, 50010
- McFarland Clinic, PC
-
Cedar Rapids, Iowa, United States, 52403
- Cedar Rapids Oncology Associates
-
Des Moines, Iowa, United States, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, United States, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, United States, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, United States, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, United States, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, United States, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Des Moines, Iowa, United States, 50307
- Mercy Capitol Hospital
-
Sioux City, Iowa, United States, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, United States, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, United States, 51104
- Mercy Medical Center - Sioux City
-
-
Kansas
-
Chanute, Kansas, United States, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, United States, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, United States, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Kingman, Kansas, United States, 67068
- Cancer Center of Kansas, PA - Kingman
-
Liberal, Kansas, United States, 67901
- Southwest Medical Center
-
Newton, Kansas, United States, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, United States, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, United States, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, United States, 67042
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, United States, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, United States, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, United States, 67214
- CCOP - Wichita
-
Wichita, Kansas, United States, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, United States, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, United States, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Massachusetts
-
Taunton, Massachusetts, United States, 02780
- Morton Hospital & Medical Center
-
-
Michigan
-
Adrian, Michigan, United States, 49221
- Hickman Cancer Center at Bixby Medical Center
-
Ann Arbor, Michigan, United States, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, United States, 48106
- CCOP - Michigan Cancer Research Consortium
-
Dearborn, Michigan, United States, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Flint, Michigan, United States, 48503
- Hurley Medical Center
-
Flint, Michigan, United States, 48503
- Genesys Hurley Cancer Institute
-
Grosse Pointe Woods, Michigan, United States, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Jackson, Michigan, United States, 49201
- Foote Memorial Hospital
-
Kalamazoo, Michigan, United States, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, United States, 49001
- Borgess Medical Center
-
Kalamazoo, Michigan, United States, 49007-3731
- West Michigan Cancer Center
-
Lambertville, Michigan, United States, 48144
- Haematology-Oncology Associates of Ohio and Michigan, PC
-
Lansing, Michigan, United States, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, United States, 48154
- St. Mary Mercy Hospital
-
Monroe, Michigan, United States, 48162
- Community Cancer Center of Monroe
-
Monroe, Michigan, United States, 48162
- Mercy Memorial Hospital - Monroe
-
Pontiac, Michigan, United States, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, United States, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, United States, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Warren, Michigan, United States, 48093
- St. John Macomb Hospital
-
-
Minnesota
-
Burnsville, Minnesota, United States, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, United States, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Edina, Minnesota, United States, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, United States, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, United States, 55350
- Hutchinson Area Health Care
-
Litchfield, Minnesota, United States, 55355
- Meeker County Memorial Hospital
-
Maplewood, Minnesota, United States, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, United States, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, United States, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, United States, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
Saint Louis Park, Minnesota, United States, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, United States, 55102
- United Hospital
-
Saint Paul, Minnesota, United States, 55101
- Regions Hospital Cancer Care Center
-
Saint Paul, Minnesota, United States, 55102
- HealthEast Cancer Care at St. Joseph's Hospital
-
Shakopee, Minnesota, United States, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
Waconia, Minnesota, United States, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, United States, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
Woodbury, Minnesota, United States, 55125
- HealthEast Cancer Care at Woodwinds Health Campus
-
-
New Jersey
-
East Orange, New Jersey, United States, 07018-1095
- Veterans Affairs Medical Center - East Orange
-
Flemington, New Jersey, United States, 08822
- Hunterdon Regional Cancer Center at Hunterdon Medical Center
-
Marlton, New Jersey, United States, 08053
- Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
-
Red Bank, New Jersey, United States, 07701
- Booker Cancer Center at Riverview Medical Center
-
Voorhees, New Jersey, United States, 08043
- Fox Chase Virtua Health Cancer Program at Virtua West Jersey
-
-
Ohio
-
Akron, Ohio, United States, 44309-2090
- Summa Center for Cancer Care at Akron City Hospital
-
Bowling Green, Ohio, United States, 43402
- Wood County Oncology Center
-
Canton, Ohio, United States, 44710-1799
- Aultman Cancer Center at Aultman Hospital
-
Elyria, Ohio, United States, 44035
- Hematology Oncology Center
-
Lima, Ohio, United States, 45804
- Lima Memorial Hospital
-
Lima, Ohio, United States, 45801
- St. Rita's Medical Center
-
Maumee, Ohio, United States, 43537
- Northwest Ohio Oncology Center
-
Maumee, Ohio, United States, 43537
- St. Luke's Hospital
-
Oregon, Ohio, United States, 43616
- St. Charles Mercy Hospital
-
Oregon, Ohio, United States, 43616
- Toledo Clinic - Oregon
-
Sandusky, Ohio, United States, 44870
- North Coast Cancer Care, Incorporated
-
Sylvania, Ohio, United States, 43560
- Flower Hospital Cancer Center
-
Tiffin, Ohio, United States, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, United States, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, United States, 43606
- Toledo Hospital
-
Toledo, Ohio, United States, 43614
- Medical University of Ohio Cancer Center
-
Toledo, Ohio, United States, 43617
- CCOP - Toledo Community Hospital
-
Toledo, Ohio, United States, 43623
- Toledo Clinic, Incorporated - Main Clinic
-
Wauseon, Ohio, United States, 43567
- Fulton County Health Center
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18015
- St. Luke's Cancer Network at St. Luke's Hospital
-
Bryn Mawr, Pennsylvania, United States, 19010
- Bryn Mawr Hospital
-
Danville, Pennsylvania, United States, 17822-0001
- Geisinger Cancer Institute at Geisinger Health
-
Hershey, Pennsylvania, United States, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Lewistown, Pennsylvania, United States, 17044
- Lewistown Hospital
-
Paoli, Pennsylvania, United States, 19301-1792
- Cancer Center of Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, United States, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Albert Einstein Cancer Center
-
Philadelphia, Pennsylvania, United States, 19107-5541
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Cancer Centers
-
Reading, Pennsylvania, United States, 19612-6052
- McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
-
Reading, Pennsylvania, United States, 19604
- St. Joseph Medical Center
-
Scranton, Pennsylvania, United States, 18501
- Mercy Hospital Cancer Center - Scranton
-
Scranton, Pennsylvania, United States, 18510
- Hematology and Oncology Associates of Northeastern Pennsylvania
-
State College, Pennsylvania, United States, 16803
- Mount Nittany Medical Center
-
State College, Pennsylvania, United States, 16801
- Geisinger Medical Group - Scenery Park
-
Wilkes-Barre, Pennsylvania, United States, 18711
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
-
Wynnewood, Pennsylvania, United States, 19096
- Lankenau Cancer Center at Lankenau Hospital
-
Wynnewood, Pennsylvania, United States, 19096
- CCOP - Main Line Health
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, United States, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, United States, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Texas
-
Temple, Texas, United States, 76508
- CCOP - Scott and White Hospital
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
- Fredericksburg Oncology, Incorporated
-
-
Wisconsin
-
Eau Claire, Wisconsin, United States, 54701
- Center for Cancer Treatment & Prevention at Sacred Heart Hospital
-
Eau Claire, Wisconsin, United States, 54701
- Marshfield Clinic Cancer Care at Regional Cancer Center
-
La Crosse, Wisconsin, United States, 54601
- Gundersen Lutheran Center for Cancer and Blood
-
Madison, Wisconsin, United States, 53792-6164
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
-
Marshfield, Wisconsin, United States, 54449
- Saint Joseph's Hospital
-
Marshfield, Wisconsin, United States, 54449
- Marshfield Clinic - Marshfield Center
-
Minocqua, Wisconsin, United States, 54548
- Marshfield Clinic - Lakeland Center
-
Rhinelander, Wisconsin, United States, 54501
- Ministry Medical Group at Saint Mary's Hospital
-
Rice Lake, Wisconsin, United States, 54868
- Marshfield Clinic - Indianhead Center
-
Stevens Point, Wisconsin, United States, 54481
- Saint Michael's Hospital Cancer Center
-
Wausau, Wisconsin, United States, 54401
- Marshfield Clinic - Wausau Center
-
Wausau, Wisconsin, United States, 54401
- University of Wisconcin Cancer Center at Aspirus Wausau Hospital
-
Wisconsin Rapids, Wisconsin, United States, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA:
Histologically or cytologically confirmed bronchoalveolar carcinoma (BAC) or adenocarcinoma of the lung with BAC features meeting 1 of the following stage criteria:
- Stage IIIB disease (with pleural or pericardial effusion)
- Stage IV disease
- Recurrent disease
- Measurable disease
- Tumor tissue available from biopsy
- Age of 18 and over
- ECOG performance status of 0-2
- Life expectancy greater than 3 months
- White blood cell (WBC) ≥ 3,000/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin normal
- Aspartate aminotransferase (AST) and/or alanine aminotranferease (ALT) ≤ 2.5 times upper limit of normal
- Creatinine normal OR Creatinine clearance ≥ 60 mL/min
- No more than 1 prior chemotherapy regimen for advanced BAC
- More than 3 years since prior chemotherapy for other malignancies
- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) for this malignancy and recovered
HIV-positive patients are eligible provided the following criteria are met:
- CD4 count ≥ 100/mm^3
- Undetectable viral load within the past 3 months
- Receiving a stable antiretroviral regimen for ≥ 4 weeks before study entry
- Fertile patients must use effective contraception
- At least 2 weeks since prior radiotherapy and recovered
EXCLUSION CRITERIA:
Untreated brain metastases
- Patients with stable brain metastases ≥ 4 weeks after external beam radiotherapy to the brain are eligible
- Acute hepatitis
- Symptomatic congestive heart failure
- Uncontrolled hypertension
- Unstable angina pectoris
- Cardiac arrhythmia
- Pregnant or nursing
- Prior allergic reaction to chimerized or murine monoclonal antibody therapy
- Documented presence of human anti-mouse antibodies
- Ongoing or active infection
- Psychiatric illness or social situation that would preclude study compliance
- Other uncontrolled illness
- Prior cetuximab
- Concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)
- Other prior known epidermal growth factor receptor inhibitors (e.g., gefitinib or erlotinib)
- Other concurrent investigational agents
- Other concurrent anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cetuximab
Cetuximab was given as a weekly intravenous (IV) infusion (over 60 minutes) at 250 mg/m2 from week 2 onwards after an initial loading dose of 400 mg/m2 (over 120 minutes) on week 1 until disease progression or unacceptable toxicity.
The infusion rate of cetuximab could not exceed 5 mL/min.
Each cycle will be 28 days in length.
To prevent a hypersensitivity reaction, all patients were premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) by IV (over 30-60 minutes) prior to the first dose of cetuximab.
Premedication might be administered prior to subsequent doses, but at the investigator's discretion, the dose of diphenhydramine (or a similar agent) was reduced.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (Proportion of Patients With Objective Response)
Time Frame: Assessed every 8 weeks during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years
|
Response was evaluated using RECIST 1.0 criteria.
Per RECIST criteria, Complete response (CR)= disappearance of all target and nontarget lesions Partial response (PR)= >=30% decrease in the sum of the longest diameters of target lesions from baseline, and persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits.
Objective response = CR + PR.
|
Assessed every 8 weeks during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Every week during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years
|
Overall survival is defined as the time from registration to death.
|
Every week during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years
|
Time to Progression
Time Frame: Assessed every 8 weeks during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years
|
Time to progression is defined as time from study entry until disease progression.
Progression is defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s) or unequivocal progression of existing nontarget lesions.
|
Assessed every 8 weeks during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years
|
Overall Survival by Smoking Status
Time Frame: Overall survival assessed every week during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years. Smoking status evaluated at baseline
|
Medians of overall survival by smoking status are reported.
|
Overall survival assessed every week during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years. Smoking status evaluated at baseline
|
Time to Progression by Smoking Status
Time Frame: Progression assessed every 8 weeks during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years. Smoking status evaluated at baseline
|
Medians of time to progression by smoking status are reported.
|
Progression assessed every 8 weeks during treatment; after off-treatment, every 3 months for 2 years and then every 6 months for 3 years. Smoking status evaluated at baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Suresh Ramalingam, MD, Emory Winship Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000409755
- U10CA021115 (U.S. NIH Grant/Contract)
- E1504 (Other Identifier: Eastern Cooperative Oncology Group (ECOG))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRecruitingHead and Neck Squamous Cell Carcinoma | Margin AssessmentNetherlands
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRecruitingColo-rectal Cancer | Capecitabine | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenTerminatedMetastatic Colorectal CancerNetherlands
-
Eben RosenthalNational Cancer Institute (NCI)TerminatedPancreatic AdenocarcinomaUnited States
-
HiberCell, Inc.TerminatedColorectal CancerUnited States, Puerto Rico, Germany, France
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCCompleted
-
Cancer Institute and Hospital, Chinese Academy...Recruiting
-
Poitiers University HospitalCompletedMetastatic Colon CancerFrance
-
Cliniques universitaires Saint-Luc- Université...Merck Sharp & Dohme LLC; Merck Serono International SACompleted